GamaMabs Pharma Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Employees
  • 7
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $16.1M
Latest Deal Amount
  • Investors
  • 7

GamaMabs Pharma General Information

Description

Developer of a biotechnology platform designed to develop innovative monoclonal antibodies in cancer. The company's biotechnology platform develops monoclonal antibodies with increased tumor cell killing properties which targets anti-mullerian human receptor in ovarian cancer, enabling physicians treat unaddressed specific target in gynecological cancers.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 1 place Pierre Potier
  • ONCOPOLE entrée B
  • 50624 Toulouse
  • France
+33 05 00 00 00 00
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

GamaMabs Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 15-Dec-2015 $16.1M 000.00 Completed Startup
2. Early Stage VC 03-Mar-2014 00.00 00.000 Completed Startup
1. Early Stage VC (Series A) 30-Sep-2013 $4.81M $4.81M Completed Startup
To view GamaMabs Pharma’s complete valuation and funding history, request access »

GamaMabs Pharma Executive Team (5)

Name Title Board Seat Contact Info
Stephane Degove Chief Executive Officer, Chief Financial Officer and Board Member
Jean-Marc Barret Ph.D Pharmacology Manager
Jean-François Prost MD Board Member & Vice President, Research & Development and Strategy
Isabelle Tabah-Fisch MD Chief Medical Officer
Thierry Hercend Ph.D Chairman
To view GamaMabs Pharma’s complete executive team members history, request access »

GamaMabs Pharma Board Members (9)

Name Representing Role Since
Benjamin Mery LFB Group Board Member 000 0000
François Thomas MD Self Board Member 000 0000
Gilles Nobécourt Andera Partners Board Member 000 0000
Jean-François Prost MD GamaMabs Pharma Board Member & Vice President, Research & Development and Strategy 000 0000
Jean-Michel Petit Institut Régional de Développement Industriel Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

GamaMabs Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GamaMabs Pharma Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Andera Partners PE/Buyout Minority 000 0000 000000 0
Institut Régional de Développement Industriel Venture Capital Minority 000 0000 000000 0
Alto Invest Asset Manager Minority 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
CDC Enterprises PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »